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The anti-cachectic effect of fatty acids 
Matthew D. Barber, James A. Ross and Kenneth C. H. Fearon” 
University Department of Surgery, Royal Infirmary of Edinburg~, E d i n b u r ~ ~  EH3 9YW, UK 
Patients with advanced cancer frequently exhibit progressive 
weight loss and this is associated with a shorter survival time 
and reduced quality of life. Indeed, some patients appear to 
die of severe wasting rather than as a result of vital organ 
involvement by tumour (Warren, 1935; DeWys et al. 1980; 
Oveson et al. 1993b). Seventy of weight loss varies mark- 
edly with tumour type; for example, some patients with 
advanced breast cancer actually increase their weight, 
whereas almost all patients with pancreatic cancer become 
severely wasted. In a recent survey of patients with 
unresectable pancreatic cancer we found that 85 % of 
patients had unintentionally lost weight by the time of diag- 
nosis and that near to the time of death the group as a whole 
had lost approximately 25 % of their pre-illness weight 
(Wigmore et al. 1997~). Clearly, in a proportion of individu- 
als with pancreatic cancer such severe weight loss contrib- 
utes to their demise, and thus it is patients with pancreatic 
cancer that we have used as a paradigm for cancer cachexia. 
The term cachexia is derived from the Greek words 
‘kakos’, meaning ‘bad’ and ‘hexis’, meaning ‘condition’. 
The syndrome is characterized by anorexia, early satiety, 
changes in taste perception, weight loss, weakness, anaemia 
and oedema (Fearon & Carter, 1988). Cachexia is not exclu- 
sive to cancer, but is also seen in a variety of inflammatory 
conditions such as sepsis, acquired immunodeficiency syn- 
drome and rheumatoid arthritis (Grunfeld & Feingold, 1992; 
Roubenoff et al. 1992; Cangiano et al. 1996). 
Mechanisms of weight loss in cancer 
For loss of weight to occur there must be a reduction in 
energy intake, an increase in energy expenditure or a combi- 
nation of the two. In pancreatic cancer it would appear that 
both reduced intake and increased expenditure apply (Fal- 
coner et al. 1994; Wigmore et al. 19974. In uncomplicated 
starvation there is an adaptation to conserve protein and 
reduce energy expenditure. In cancer cachexia these adapta- 
tions do not appear to compensate adequately, and a situation 
more akin to the so-called ‘metabolic response to trauma’ 
develops, with continuing breakdown of body stores and 
increased energy expenditure (Falconer et al. 1994; Brennan, 
1997). A wide spectrum of changes in nutrient metabolism 
is seen in weight-losing cancer patients. Insulin resistance, 
glucose intolerance, increased glucose production and con- 
sumption, and increased Con cycle activity have all been 
demonstrated (Chlebowski et al. 1982; EdCn et al. 1984; 
Holroyde et al. 1984; Shaw & Wolfe, 1987). A decrease in 
lipogenesis is seen due to decreased lipoprotein lipase (EC 
3.1.1.34) activity (Jeevanandam et al. 1986; Vlassara et al. 
1986). Protein turnover is altered (Fearon et al. 1988; 
Melville et al. 1990) and this may be closely related to the 
development of an hepatic acute-phase response. 
At diagnosis about 40 % of patients with advanced pancre- 
atic cancer display an acute-phase protein response. Close to 
the time of death this proportion rises to 80 % (Falconer et al. 
1995). The acute-phase protein response is an alteration in 
the balance of protein production by the liver, usually in 
response to injury, trauma or infection, in an attempt to aid 
the prevention of ongoing tissue damage, the eradication of 
infecting organisms and the activation of repair processes 
(Baumann & Gauldie, 1994). The presence of an acute-phase 
protein response in pancreatic cancer patients, as measured 
by an elevated serum C-reactive protein level, is strongly 
associated with a shorter survival (Falconer et al. 1995). It 
has been suggested that an imbalance between the amino 
acid composition of acute-phase proteins and skeletal mus- 
cle, the body’s labile amino acid reserve, helps drive the 
accelerated wasting seen during an acute-phase response 
(Reeds et al. 1994). 
Overall, these metabolic changes result in a diversion of 
nutrients away from peripheral tissues and increased expen- 
diture of energy. In the acute situation, such as trauma or 
infection, the net effect is presumably beneficial in supplying 
the nutrients and proteins to aid the defence of the body, but 
in a chronic condition such as cancer these changes can lead 
to accelerated loss of lean tissue. 
Anorexia in patients with advanced cancer can often be 
due to obstruction of the gastrointestinal tract, pain, depres- 
sion, anxiety, steatorrhoea, constipation, general debility and 
the effects of treatments such as opiates, radiotherapy and 
chemotherapy. However, there remain many patients with 
advanced cancer in whom there is no overt cause of a reduced 
food intake. Weight loss can begin early in the course of 
malignant disease and the degree of wasting may correlate 
poorly with tumour burden. Thus, it would appear that, in 
some individuals, the anorexia and metabolic changes of 
cachexia are driven by mediators produced either by the 
tumour directly or by the body in response to the tumour. 
Mediators of the cachectic state 
Cytokines, including tumour necrosis factor, interleukins-1 
and -6, ciliary neurotrophic factor and interferon-y have been 
shown to induce some of the features of cachexia following 
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administration to animals or human subjects (Michie et al. 
1988; Starnes et al. 1988; Hellerstein et al. 1989; Strassmann 
et al. 1992; Espat et al. 1996). Elevated serum levels of 
tumour necrosis factor and interleukin-6 and the soluble 
receptors for tumour necrosis factor have been found in can- 
cer patients, and in some instances these have correlated with 
severity of disease or weight loss (Aderka et al. 1991; Knapp 
et al. 1991; Kurzrock et al. 1993; Falconer et al. 1994; Pres- 
ton et al. 1995; Staal-van den Brekel et al. 1995). However, 
often the pattern of symptoms and metabolic changes pro- 
duced by exogenous cytokines differs from that of classical 
cachexia, and antibody-blocking experiments have shown 
only a limited ability to reverse these changes (Mahoney et 
al. 1988; Langstein &Norton, 1991; McNamara et al. 1992). 
Thus, the relevance of cytokines within the circulation may 
only be limited. Increased production of tumour necrosis 
factor and interleukm-6 by isolated peripheral-blood 
mononuclear cells of patients with cancer has also been 
observed and is in keeping with a local action for these 
cytokines (Aderka et al. 1985; Falconer et al. 1994). In pan- 
creatic cancer such enhanced cytokine production correlates 
well with hypermetabolism and an acute-phase response 
(Falconer et a1. 1994). Most of the pro-inflammatory 
cytokines, but primarily interleukin-6, have been shown to 
induce the hepatic acute-phase protein response (Heinrich 
et al. 1990; Oldenburg et al. 1993; O’Riordain er al. 1995; 
Espat et al. 1996). Thus, cytokines are likely to work in vivo 
at a local level through a complex network of interrelation- 
ships, they stimulate acute-phase protein production and 
probably also play a wider role in cachexia. 
The source of pro-inflammatory cytokines in cancer 
cachexia is not clearly established. Tumour cells may 
produce pro-inflammatory cytokines themselves (Wigmore 
et al. 1994) and host peripheral-blood mononuclear cells 
may produce these cytokines in response to the presence of 
the tumour (Falconer et al. 1994). In addition there would 
appear to be amplification loops involving the tumour, with 
interaction of two or more cytokines (Yasumoto et al. 1995). 
It is also possible that the host further modulates the response 
to the cytokine network since neuroendocrine hormones will 
affect the production of acute-phase proteins (O’fiordain 
et al. 1995). Different clones of cancer cell lines produce 
similar patterns of cytokines in mouse models but have very 
different effects on host weight (Soda et al. 1994). It appears 
that this may be due to the production of other tumour- 
specific cachectic factors in association with conventional 
cytokines. 
Changes in neuroendocrine hormone levels and target- 
organ sensitivity are also observed in cachexia. In weight- 
stable patients with pancreatic cancer, increased insulin 
secretion has been found with peripheral insulin resistance 
(Gullo et al. 1993). However, in trials in which weight-losing 
patients were included, a markedly reduced insulin response 
to feeding was seen. Changes in insulin production seem to 
be unrelated to loss of pancreatic tissue (Schwartz et al. 
1978; Fox et al. 1985; Cersosimo et al. 1991). Elevated 
cortisol and glucagon levels have also been described 
(Schaur et al. 1979; Burt et al. 1983; Holroyde et al. 1984). 
These changes may be stimulated by cytokines (Michie et al. 
1988; Starnes et al. 1988) and may tend to amplify the 
acute-phase response (Baumann & Gauldie, 1994). Infusion 
of hydrocortisone or cortisol, glucagon and adrenalin in 
human subjects produces many of the features of the acute- 
phase response, including increased energy expenditure, 
negative N balance, C-reactive protein production and 
glucose intolerance (Bessey et al. 1984; Watters et al. 1986). 
The role of leptin (the recently identified protein produced 
by adipocytes which regulates food intake and body weight) 
in cachexia remains to be clarified. The production and 
end-organ effects of leptin are modulated by cytokines and 
glucocorticoids, thus it may have a part to play in mediating 
cachexia (Grunfeld et al. 1996; Schwarz et aZ. 1997). 
It is also possible that novel tumour-specific factors may 
mediate weight loss in cancer. A 24 kDa glycoprotein found 
in the urine of cachectic cancer patients has recently been 
characterized. This causes enhanced skeletal muscle proteol- 
ysis when given to mice, and appears distinct from known 
cytokines (McDevitt et al. 1995; Todorov et al. 1996; Cariuk 
et al. 1997). A lipid-mobilizing factor similar to zinc-a2- 
glycoprotein (an acute-phase protein) has also been isolated 
from the urine of cachectic cancer patients. This produces 
marked lipolysis in mouse models and in human adipocytes 
cultured in vitro (Tisdale, 1996). 
Treatment of weight loss in cancer 
The best way to cure cancer cachexia is to cure the cancer. 
However, this is only an option for the minority of patients. 
The next most obvious way to treat this phenomenon would 
be to supplement nutritional intake. However, studies of 
hyperalimentation in cancer cachexia using enteral or 
parenteral supplementation have been disappointing, 
producing only limited weight gain, mainly of water and 
€at (Nixon et al. 1981; Cohn et al. 1982; Evans et al. 1985; 
Klein et al. 1986; Lipman, 1991; Ng & Lowry, 1991). Oral 
supplementation is often limited by anorexia and early 
satiety, but even when a limited increase in energy and N 
intake has been achieved this has not led to significant weight 
gain or clinical benefit (Oveson et a2. 1993~).  
Numerous other agents have been suggested to be useful 
in cachexia, such as the anti-serotoninergic agent cypro- 
heptadine, the pro-kinetic agent metoclopramide, the 
corticosteroid dexamethasone, the progestogens medroxy- 
progesterone acetate and megestrol acetate, the gluconeo- 
genesis inhibitor hydrazine sulphate and the psychotropic 
agent tetrahydrocannabinol, but none has lived up to its 
promise (Chlebowski et al. 1987; Beck & Tisdale, 1989, 
1990; McMillan et al. 1994; Nelson et al. 1994; Gebbia et al. 
1996; Simons et al. 1996) and many of these agents have sig- 
nificant additional side-effects. 
n-3 Polyunsaturated fatty acids 
Eicosapentaenoic acid is the major metabolically-active n-3 
fatty acid in man. It is made by marine algae and is found in 
the diet as a component of fish oil. 
Fish oil supplements rich in n-3 fatty acids have been 
shown to reduce production of the cytokines interleukin-1, 
interleukin-6 and tumour necrosis factor by mononuclear 
cells in normal volunteers, and this effect is maintained for 
some weeks after stopping supplementation (Endres et al. 
1989; Cooper et al. 1993; Meydani et al. 1993). Fish oil also 
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increases T-suppressor : helper cells, decreases T-cell 
proliferative response to mitogens, decreases the delayed- 
hypersensitivity skin response and reduces neutrophil 
chemotaxis (Lee et al. 1985; Endres et al. 1989; Meydani 
et al. 1993; Calder, 1996). 
Eicosapentaenoic acid has also been shown to inhibit fat 
and protein breakdown in animal models of cancer cachexia 
(Tisdale, 1996), and it has been suggested that this fs due to 
inhibition of the end-organ effects of tumour-derived 
lipolytic and proteolytic factors. Furthermore, eicosa- 
pentaenoic acid may modify the response of hepatocytes to 
pro-inflammatory cytokines in terms of acute-phase protein 
production (Wigmore et al. 1997b). 
Thus, it would seem that n-3 fatty acids can affect not only 
the production of pro-inflammatory mediators but also 
their end-organ effects. There are numerous mechanisms by 
which this may occur. Polyunsaturated fatty acids influence 
the activity of a number of receptors and enzymes which 
have a fundamental role in cellular signalling. When agonists 
stimulate receptors in the cell membrane they may activate 
adenylate cyclase (EC 4.6.1.1) or a phospholipase, the 
second messenger products of which (lipids in the case of 
phospholipases) influence the actions of CAMP-dependent 
protein kinase and protein kinase C respectively. n-3 Fatty 
acids have been shown to influence the effects of adenylate 
cyclase (Alam et al. 1988; Tisdale, 1993), phospholipase A2 
(EC 3.1.1.4) (Ballou & Cheung, 1985), CAMP-dependent 
protein kinase (Speizer et al. 1991) and protein lunase C 
(Speizer et al. 1991; Holian & Nelson, 1992). Eicosa- 
pentaenoic acid also binds to membrane voltage-sensitive Na 
channels and may alter the conductance of the channel (Kang 
& Leaf, 1996), and n-3 fatty acids bind to the cytoplasmic 
glucocorticoid receptor at a site different from the hormone- 
binding site and markedly reduce its affinity for the hormone 
(Vallette et al. 1991; Sumida et al. 1993). 
Other mechanisms by which n-3 fatty acids may modulate 
inflammation include interaction with peroxisome 
proliferator-activated receptor-a which is a gene transcrip- 
tion factor that induces the breakdown of leukotrienes and, 
thus, has a role in limiting the duration and extent of inflam- 
mation. A variety of polyunsaturated fatty acids, including 
eicosapentaenoic acid, and leukotrienes themselves appear 
to increase the activity of this factor (Keller et al. 1993; 
Devchand et al. 1996). Alternatively, the C20 polyunsatu- 
rated fatty acids are metabolized by cyclo-oxygenase into the 
prostanoids, prostaglandins and thromboxanes, and by 
5-lipoxygenase (EC 1.13.11.12) into the leukotrienes. The 
n-6 fatty acid arachidonic acid is the major precursor for 
these substances in man and gives rise to the 2-series 
prostanoids (e.g. thromboxane A2 and prostglandin E2 and 12) 
and the 4-series leukotrienes (leukotriene B4, C4 etc.). In con- 
trast, eicosapentaenoic acid is also metabolized by these 
enzymes, but into the 3-series prostanoids and 5-series 
leukotrienes. Leukotrienes are involved in regulating inflam- 
matory responses. 5-Series leukotrienes are less active and 
compete with those of the 4-series for binding sites, resulting 
in anti-inflammatory effects (Fischer & Weber, 1983; Lee 
et al. 1985; Leaf & Weber, 1988; Fitzgerald et al. 1989; 
NordOy & Dyerberg, 1989; Schmitt & Dyerberg, 1989). 
Clinical studies using eicosapentaenoic acid-based 
preparations in cancer cachexia 
We have hypothesized that there is a block to the accretion 
of lean body mass in cachectic patients, in part, attributable 
to enhanced pro-inflammatory cytokine release. By down- 
regulating cytokine production, fish oil or eicosapentaenoic 
acid supplementation should modulate this pro- 
inflammatory state. To test whether supplementation with 
fish oil could affect the progress of cachexia in patients 
with advanced pancreatic cancer we have conducted a study 
using Maxepa (Seven Seas, Hull, UK), a mixed marine 
triacylglycerol preparation containing (gkg) 180 
eicosapentaenoic acid and 120 docosahexaenoic acid. This 
was given orally at a median dose of 12 gld (equivalent to 
2 g eicosapentaenoic acid/d) to eighteen patients with 
unresectable pancreatic cancer. Before treatment, all patients 
were losing weight at a median rate of 2.9 kg/month. After 
supplementation for 3 months, patients had a median weight 
gain of 0.2 kg/month with less than half the patients continu- 
ing to lose weight. There was no change in the percentage 
total body water over the period of the study. This regimen 
also produced a fall in the serum C-reactive protein level, 
suggesting that some of the metabolic abnormalities of pan- 
creatic cancer can be reversed, resulting in the stabilization 
of weight (Wigmore et al. 1996b). 
Subsequently we have examined the role of eicosa- 
pentaenoic acid alone in reversing cachexia. Twenty-seven 
patients with unresectable pancreatic cancer were given 6 g 
eicosapentaenoic acid (95 % pure)/d orally after a 4-week 
dose-escalation period. Patients were losing a median of 
2.0 kglmonth at baseline. After 4 weeks patients had a 
median weight gain of 0.75 kg, and this effect remained at 3 
months with a median weight gain of 0.25 kglmonth. Again, 
there was no change in the percentage total body water over 
the course of the study, confirming that the achievement of 
weight stability was not due to changes in hydration (Barber 
et al. 1997). There were no serious side-effects in these 
studies and median survival was approximately 7 months. 
A subgroup of six patients from the latter study underwent 
measurement of interleukin-6 and tumour necrosis factor 
production in peripheral-blood mononuclear cells ex vivo 
and of the acute-phase protein response in vivo before and 
after the administration of eicosapentaenoic acid for 
the l-month dose-escalation period. These patients showed 
a significant fall in their mononuclear cell production of 
pro-inflammatory cytokines and a fall in the level of the 
acute-phase response as measured by C-reactive protein 
(Wigmore et al. 1996a, 1997~).  
Eicosapentaenoic acid, therefore, would seem capable of 
arresting the further development of cachexia in patients with 
advanced pancreatic cancer. This may be related specifically 
to the down-regulation of pro-inflammatory cytokine- 
mediated metabolic events. Perhaps more likely, however, 
is a complex interaction between eicosapentaenoic acid and 
the production or end-organ effects of (a) protein and lipid 
mediators of the inflammatory response, (b) tumour-specific 
catabolic mediators and (c) counter-regulatory neuro- 
endocrine hormones. 
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Conclusion 
The previously described phase 1 and 2 clinical studies with 
eicosapentaenoic acid in patients with cancer cachexia point 
to a potential role for lipids as modulators of the wasting pro- 
cess. The precise contribution from the specific and 
non-specific components of the immune system to the gener- 
ation of the inflammatory mediators involved in cancer 
cachexia in human subjects is poorly understood. However, 
if current randomized phase 3 studies with eicosapentaenoic 
acid prove effective, then this should at least provide a model 
for further study of the interaction between lipids and the role 
of the immune system in the wasting associated with a vari- 
ety of human diseases. 
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